ACAD
37.44
+0.65
+1.77%
AEMD
6.399
+0.099
+1.571%
APRI
0.32
-0.028
-7.9310%
ARNA
1.71
+0.04
+2.40%
ATEC
0.36
-0.01
-2.6757%
CNAT
2.34
+0.01
+0.43%
CRXM
0.175
-0.004
-2.235%
CYTX
2.03
+0.02
+1.00%
DXCM
88.66
+0.34
+0.38%
GNMK
10.1
+0.13
+1.30%
HALO
9.93
+0.41
+4.31%
ILMN
162.25
+12.15
+8.09%
INNV
0.5
-0.1
-16.67%
INO
9.65
+0.1
+1.05%
ISCO
1.93
-0.07
-3.50%
ISIS
57.56
0.00
0.00%
LGND
136.07
+1.82
+1.36%
LPTN
2.08
+0.11
+5.58%
MBVX
0.63
-0.01
-1.56%
MEIP
1.38
-0.01
-0.72%
MNOV
6.09
-0.16
-2.56%
MRTX
4.84
+0.14
+2.98%
MSTX
0.365
+0.015
+4.286%
NBIX
50.82
+1.2
+2.42%
NUVA
60.65
-1.35
-2.18%
ONCS
1.72
-0.03
-1.71%
ONVO
4.33
+0.13
+3.10%
OREX
3.5
+0.23
+7.03%
OTIC
14.78
+0.32
+2.21%
QDEL
21.05
+0.2
+0.96%
RCPT
231.96
0.00
0.00%
RGLS
4.1
+0.58
+16.48%
RMD
65.13
-0.82
-1.24%
SPHS
5.11
-0.53
-9.40%
SRNE
6.21
0.00
0.00%
TROV
5.69
+0.36
+6.75%
VICL
4.2
+0.01
+0.24%
VOLC
18
0.00
0.00%
ZGNX
9.1
+0.15
+1.68%
ACAD
37.44
+0.65
+1.77%
AEMD
6.399
+0.099
+1.571%
APRI
0.32
-0.028
-7.9310%
ARNA
1.71
+0.04
+2.40%
ATEC
0.36
-0.01
-2.6757%
CNAT
2.34
+0.01
+0.43%
CRXM
0.175
-0.004
-2.235%
CYTX
2.03
+0.02
+1.00%
DXCM
88.66
+0.34
+0.38%
GNMK
10.1
+0.13
+1.30%
HALO
9.93
+0.41
+4.31%
ILMN
162.25
+12.15
+8.09%
INNV
0.5
-0.1
-16.67%
INO
9.65
+0.1
+1.05%
ISCO
1.93
-0.07
-3.50%
ISIS
57.56
0.00
0.00%
LGND
136.07
+1.82
+1.36%
LPTN
2.08
+0.11
+5.58%
MBVX
0.63
-0.01
-1.56%
MEIP
1.38
-0.01
-0.72%
MNOV
6.09
-0.16
-2.56%
MRTX
4.84
+0.14
+2.98%
MSTX
0.365
+0.015
+4.286%
NBIX
50.82
+1.2
+2.42%
NUVA
60.65
-1.35
-2.18%
ONCS
1.72
-0.03
-1.71%
ONVO
4.33
+0.13
+3.10%
OREX
3.5
+0.23
+7.03%
OTIC
14.78
+0.32
+2.21%
QDEL
21.05
+0.2
+0.96%
RCPT
231.96
0.00
0.00%
RGLS
4.1
+0.58
+16.48%
RMD
65.13
-0.82
-1.24%
SPHS
5.11
-0.53
-9.40%
SRNE
6.21
0.00
0.00%
TROV
5.69
+0.36
+6.75%
VICL
4.2
+0.01
+0.24%
VOLC
18
0.00
0.00%
ZGNX
9.1
+0.15
+1.68%
Home » Archive by Category

Syndication

Software Test Engineer – On-Board Services – San Diego, CA

July 25, 2016 – 1:03 pm

Fortune 500 Biotech Company. They would be responsible for mapping design requirements into test protocols and execution of product testing against product…$54 – $59 an hour
From On-Board Services – 25 Jul 2016 20:03:47 GMT
– …

Software Test Engineer – On-Board Services – San Diego, CA

July 25, 2016 – 1:03 pm

Fortune 500 Biotech Company. They would be responsible for mapping design requirements into test protocols and execution of product testing against product… $54 – $59 an hourFrom On-Board Services – Mon, 25 Jul 2016 20:03:47 GMT – View all San Diego …

Software Test Engineer (V&V) – On-Board Services – San Diego, CA

July 25, 2016 – 1:03 pm

Fortune 500 Biotech Company. They would be responsible for mapping design requirements into test protocols and execution of product testing against product…$54 – $59 an hour
From On-Board Services – 25 Jul 2016 20:03:47 GMT
– …

Research Associate – Job Opportunity (San Diego)

July 25, 2016 – 10:29 am

Kelly Scientific is seeking Research Associates. We have a number of open positions with our clients in San Diego. Seeking candidates with experience in ELISA, cell culture, PCR, and chemistry. Degree in a life science required. Local candidates only […

Education Outreach Assistant (La Jolla)

July 25, 2016 – 9:47 am

Job #F272
Laboratory/Department: Education Outreach
Education Outreach oversees a broad program of activities aimed at bringing the excitement of science and scientific discovery to the San Diego community. These activities include several efforts […

Multiple Chemist Openings

July 25, 2016 – 8:11 am

Our Chemistry labs are in desperate need of full time Chemists.
Multiple departments hiring for:
QC Chemist
Production Chemist
Development Chemist
Assistant Chemist
Ideal techniques/skills may include but are not limited to: HPLC, GC, LCMS, FTI […

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA

July 25, 2016 – 6:00 am

SAN DIEGO, July 25, 2016 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed the enrollment and dosing of patients in its ongoing Phase 1b trial evaluating its investigational new drug, PEGPH20, in combination with KEYTRUDA (pembrolizumab) in patients with advanced non-small cell lung and gastric cancers under a revised clinical protocol.

The revised protocol has been submitted to all institutional review boards (IRB) and is pending feedback from the FDA. The majority of IRBs have completed their review and approved the revised protocol allowing the study to resume. 

The Phase 1b study will enroll up to approximately 80 patients at a number of leading sites in the United States. For more information, go to www.clinicaltrials.gov and reference NCT02563548.

For information on KEYTRUDA, please go to www.keytruda.com.

About PEGPH20

PEGPH20 (PEGylated recombinant human hyaluronidase) targets the degradation of hyaluronan (HA), a chain of natural sugars that can accumulate around cancer cells, inhibiting other therapies. By degrading HA, PEGPH20 may increase the access of co-administered chemotherapeutic and immunotherapeutic agents.

FDA granted orphan drug designation to PEGPH20 for treatment of pancreatic cancer and fast track for PEGPH20 in combination with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer. Additionally, the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency, designated investigational drug PEGPH20 an orphan medicinal product for the treatment of pancreatic cancer.

About Halozyme

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, the possible method of action of PEGPH20, its potential application to improve cancer therapies and statements concerning future actions and clinical trials relating to the development of PEGPH20) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, clinical trials and the companion diagnostic not producing the results we expect, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company’s Annual Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2016.

Contacts:
Jim Mazzola
858-704-8122
ir@halozyme.com

Chris Burton
858-704-8352
ir@halozyme.com

Photo – http://photos.prnewswire.com/prnh/20100302/LA63139LOGO

 

SOURCE Halozyme Therapeutics, Inc.

Environmental Laboratory seeking Experienced Analyst/Supervisor (National City)

July 25, 2016 – 4:40 am

Metropolitan Solutions
National City, CA
We are a growing CA ELAP accredited environmental testing laboratory in National City, CA. Because of our growth and upcoming work projects, we are seeking experienced laboratory staff to fill a variety of r […

Epilepsy Drugs Market Size To Reach $5.47 Billion By 2024: Grand View Research, Inc.

July 25, 2016 – 4:30 am

SAN FRANCISCO, July 25, 2016 /PRNewswire/ — The global epilepsy drugs market is expected to reach over USD 5,474.14 million by 2024, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness training to the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Access full research report: http://www.grandviewresearch.com/industry-analysis/epilepsy-drugs-market 

Key Findings:

  • The second generation anti-epileptic drug class is estimated to have over 30% market share in 2015 owing to the high prescription rates, improved tolerability, and increased efficacy due to the novel mechanisms of action of these drugs
  • The third generation anti-epileptic drug class is expected to witness the fastest growth with a CAGR of over 4% over the forecast period. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • The growing need to improve the efficacy of the existent drugs and the need to develop new and enhanced anti-epileptic drugs to minimize the associated side-effects, such as dizziness, fatigue, weight gain, and depression are the propelling factors expected to drive the market growth over the forecast period.
  • North America dominated the market in terms of revenue with over USD 2,000 million in 2015 owing to the presence of well-established healthcare infrastructure, favorable government initiatives directed at the betterment of the healthcare system, and the presence of extensive research and development activities

Market Segmentation:

  • Global Epilepsy Drug market (Revenue, USD Million, 2013 – 2024)

    • First generation anti-epileptic drug
    • Second generation anti-epileptic drug
    • Third generation anti-epileptic drug
  • Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2013 – 2024)
    • North America

      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
    • Asia Pacific
      • India
      • China
    • Latin America
      • Brazil
    • MEA
      • South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: www.grandviewresearch.com 

Logo – http://photos.prnewswire.com/prnh/20160524/371361LOGO

 

SOURCE Grand View Research, Inc.

Epilepsy Drugs Market Size To Reach $5.47 Billion By 2024: Grand View Research, Inc.

July 25, 2016 – 4:30 am

SAN FRANCISCO, July 25, 2016 /PRNewswire/ — The global epilepsy drugs market is expected to reach over USD 5,474.14 million by 2024, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness training to the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Access full research report: http://www.grandviewresearch.com/industry-analysis/epilepsy-drugs-market 

Key Findings:

  • The second generation anti-epileptic drug class is estimated to have over 30% market share in 2015 owing to the high prescription rates, improved tolerability, and increased efficacy due to the novel mechanisms of action of these drugs
  • The third generation anti-epileptic drug class is expected to witness the fastest growth with a CAGR of over 4% over the forecast period. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • The growing need to improve the efficacy of the existent drugs and the need to develop new and enhanced anti-epileptic drugs to minimize the associated side-effects, such as dizziness, fatigue, weight gain, and depression are the propelling factors expected to drive the market growth over the forecast period.
  • North America dominated the market in terms of revenue with over USD 2,000 million in 2015 owing to the presence of well-established healthcare infrastructure, favorable government initiatives directed at the betterment of the healthcare system, and the presence of extensive research and development activities

Market Segmentation:

  • Global Epilepsy Drug market (Revenue, USD Million, 2013 – 2024)

    • First generation anti-epileptic drug
    • Second generation anti-epileptic drug
    • Third generation anti-epileptic drug
  • Epilepsy Drugs Regional Outlook (Revenue, USD Million, 2013 – 2024)
    • North America

      • U.S.
      • Canada
    • Europe
      • UK
      • Germany
    • Asia Pacific
      • India
      • China
    • Latin America
      • Brazil
    • MEA
      • South Africa

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: www.grandviewresearch.com 

Logo – http://photos.prnewswire.com/prnh/20160524/371361LOGO

 

SOURCE Grand View Research, Inc.